Ayurvedic Ads and the 54 Diseases You Cannot Claim
The Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 treats the label as an advertisement and lists 54 conditions no drug may be advertised to treat. It sits on top of every consumer-protection rule you already follow.
- Under the 1954 Act a label and a wrapper are advertisements, so pack copy, reels and live sessions all sit inside the same prohibition.
- Section 3 bars three purposes outright and adds every condition in the Schedule, which runs to 54 entries and includes obesity, fevers in general and nervous debility.
- Rule 170 pre-approval for Ayurvedic, Siddha and Unani advertisements is gone, but nothing that prohibited the underlying claim went with it.
- Section 13 makes this Act additional to consumer law, so a fully substantiated claim to treat a Schedule disease is still prohibited.
Most Indian consumer brands learn the advertising rules through the consumer-protection lane: substantiate the claim, do not disparage, keep the front of pack honest. An Ayurvedic brand carries all of that plus a criminal statute from 1954.
The Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954, Act 21 of 1954, came into force on 1 April 1955. It is short, it is specific, and it reaches the pack.
Under this Act the label is the advertisement
Section 2(a) defines advertisement to include any notice, circular, label, wrapper or other document, and any announcement made orally or by any means of producing or transmitting light, sound or smoke. The label is named, and so is an announcement made orally, which is how a live session and a creator reel land inside a statute drafted before Indian television existed.
Section 2(b) defines drug for this Act separately and wider: a medicine for internal or external use, any substance intended for the diagnosis, cure, mitigation, treatment or prevention of disease, and any article other than food intended to affect or influence in any way the structure or any organic function of the body. Ayurvedic medicines sit inside that comfortably. So do a good many things sold as wellness.
Three standing prohibitions and a list of 54
Section 3 prohibits taking any part in the publication of an advertisement referring to a drug in terms which suggest, or are calculated to lead to, its use for the procurement of miscarriage or prevention of conception in women, the maintenance or improvement of the capacity of human beings for sexual pleasure, or the correction of menstrual disorders in women.
Section 3(d) then adds the diagnosis, cure, mitigation, treatment or prevention of any disease, disorder or condition specified in the Schedule. The Schedule runs to 54 entries. Cancer is 6, diabetes is 9, heart diseases is 26, obesity is 38, female diseases in general is 18, fevers in general is 19, nervous debility is 37 and stature of persons is 47.
Read that list again, because it is where Ayurvedic copy usually dies. Not all the entries are serious illnesses. Several are the benefit language a wellness brand reaches for first. The proviso to section 3(d) also lets the central government add conditions by rules.
Section 4 is a separate prohibition, whatever the disease. No advertisement relating to a drug may contain matter which directly or indirectly gives a false impression of the true character of the drug, makes a false claim for it, or is false or misleading in any material particular.
Magic remedy is a defined term
Section 2(c) defines magic remedy to include a talisman, mantra, kavacha and any other charm alleged to possess miraculous powers for the diagnosis, cure, mitigation, treatment or prevention of disease, Section 5 bars a person carrying on, or purporting to carry on, the profession of administering magic remedies from advertising one as efficacious for any section 3 purpose.
That is narrower than the title of the Act suggests. For a packaged goods brand the operative sections are 3 and 4.
What the pack is judged against
The pack has a second exposure under the Drugs and Cosmetics Act, 1940. Section 33E deems an Ayurvedic, Siddha or Unani drug misbranded if it is made to appear of better or greater therapeutic value than it really is, if it is not labelled in the prescribed manner, or if its label or container or anything accompanying it bears a statement or design which makes a false claim or is false or misleading in any particular.
Better or greater therapeutic value than it really is does a great deal of work in that clause, and it is a statutory test rather than a code of practice. It sits on top of the particulars rule 161 of the Drugs and Cosmetics Rules, 1945 requires on the innermost container. The front of pack discipline we have written about for food applies here in addition, not instead.
Pre-approval went away, the prohibition did not
Rule 170 of the Drugs and Cosmetics Rules, 1945, inserted in 2018, required approval and a unique identification number from the state licensing authority before an Ayurvedic, Siddha or Unani drug could be advertised. The Ministry of Ayush notified its omission on 1 July 2024. The Supreme Court stayed that omission on 27 August 2024, then in August 2025 vacated the stay and disposed of the petition, leaving parties free to go to the High Courts.
The pre-clearance step is gone and every prohibition that sat above it is intact. Losing a permission regime is not the same as gaining permission. It moves the check from a licensing officer to a magistrate.
How it stacks with the rules you follow
Section 13 says the provisions of this Act are in addition to, and not in derogation of, any other law in force. Consumer-protection law, the advertising codes and your own claim substantiation file all still apply. This Act is not a standard you clear, it is a floor underneath them. Evidence does not rescue a claim section 3 prohibits outright: a perfectly substantiated claim to treat a Schedule disease is still prohibited. Comparison and disparagement, covered in comparative advertising, are a separate check again.
Rule 3 of the Drugs and Magic Remedies (Objectionable Advertisements) Rules, 1955 adds a step. A person authorised by the state government, if satisfied that a drug advertisement contravenes section 4, may order the manufacturer, packer, distributor or seller to furnish information on the composition or ingredients of the drug for scrutiny of the advertisement. Failure to comply is deemed a contravention of section 4. Distributor and seller are both named, so the notice can land on a marketplace seller who did not write the copy.
Two provisions matter to whoever signs off. Section 9 makes the person who at the time of the offence was in charge of and responsible to the company for the conduct of its business liable alongside the company, subject to a defence of no knowledge or due diligence, and section 9-A makes offences cognizable. Section 7 sets the penalty at imprisonment which may extend to six months on a first conviction and to one year on a subsequent one, or with fine, or with both. The Act names no figure for that fine, so nobody can price this as a cost of doing business.
The control that works is unglamorous. Keep the 54 Schedule entries beside the claim matrix, as a gate that runs before substantiation and not after it.